Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Healthcare Extenders Can Reduce Physician Burden & Improve Patient Access & Care

Kimberly Steinbarger, PT, MHS, DHSc, & Saba Mohiuddin, PharmD, BCACP  |  Issue: August 2021  |  August 11, 2021

insta_photos / shutterstock.com

insta_photos / shutterstock.com

In the early 1900s, the treatment for rheumatic and musculoskeletal disease (RMD) was primarily targeted at symptomatic relief and included analgesics, physical therapy, splinting and bed rest. With the discovery of methotrexate and its impact on rheumatoid arthritis (RA) management, a much-needed evolution of medications targeting disease activity began.

Over the past 30 years, several med­ications have been added to the armamentarium for rheumatic diseases, starting with medications now considered disease-modifying anti-rheumatic drugs (e.g., sulfasalazine, hydroxychloroquine, methotrexate). With the late 1990s came biologic therapies, including monoclonal antibodies and genetically engineered proteins that target cytokines and cell surface molecules.1

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

This pharmacologic evolution has greatly improved the lives of those with RMD; however, work disability, fatigue and the need for psychosocial support remain concerns. Team-based interventions, including non-pharmacologic, have also emerged as priorities for both patients and provider teams.

Patient and provider opinions differ regarding treatment priorities.2,3 Physicians excel at tracking the number of swollen joints, pain level, labs and global measures, but patients would also like their fatigue, stiffness, self-management, participation, sleep, emotional distress and daily functioning addressed. This is much more than a rheumatologist can address in an office appointment, especially in areas of the country with limited access to specialists.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Enter the healthcare extender.

A holistic approach to caring for patients with RMD goes beyond the medications that help prevent disease progression and damage. It requires a team of practitioners, each with their own expertise, to contribute to an individual’s quality of life.

To help meet the needs of the patient population with RMD, rheumatologists can look to advanced practice providers (APPs), including physical therapists (PTs), occupational therapists (OTs) and pharmacists. Other APPs that rheumatology practices should consider to meet varying patient needs are physician assistants (PAs), nurse practitioners (NPs), dietitians and social workers. Developing relationships with these practitioners early in their disease process can help patients preserve function, reduce pain and increase their ability to participate in activities of daily living.4

PTs

PTs can do much more than help patients with a hot joint to improve function. They can develop individualized physical activity plans for patients and suggest changes patients can make to adapt to the cyclical nature of their disease.

Doctorally prepared PTs are at the forefront of prevention and wellness for those with neuromusculoskeletal conditions and are starting to make inroads into primary healthcare.5 They are important patient advocates in developing accommodation plans in line with the Americans with Disabilities Act. They are experts in non-pharmacological pain management, particularly as it affects mobility, activity, fatigue and sleep.

Page: 1 2 3 | Single Page
Share: 

Filed under:Interprofessional PerspectiveWorkforce Tagged with:Advanced Practice CliniciansAssociation of Rheumatology Professionals (ARP)dietitiannurse practitioneroccupational therapistspharmacistphysical therapistphysician assistantssocial worker

Related Articles

    What Physical & Occupational Therapists Wish Rheumatologists Knew

    June 17, 2019

    Kim Steinbarger, PT, MHS, knows how physical and occupational therapy can make a difference for patients with rheumatic diseases. Ms. Steinbarger was just two years into her career as a physical therapist (PT) when she was diagnosed with rheumatoid arthritis (RA) in 1991. “I’ve seen how regular exercise serves as an important tool in managing…

    Essential Collaboration: Rheumatologists & PTs Must Work Together

    July 14, 2017

    The importance of rheumatologists and physical therapists (PTs) working together for patients cannot be understated. Carol Oatis, PT, PhD, says, “Rheumatologists and PTs have very similar goals. … Collaboration is essential for optimal outcomes.”…

    Medium-sized blood vessels are seen in the dermis and at the dermal-subcutaneous junction. The black arrow identifies a venule, and the blue arrow points to a fibrin deposition in the vessel wall. Extravasated neutrophils and erythrocytes are seen in the interstitium.

    Case Report: A Polyarteritis Nodosa Conundrum

    March 14, 2022

    Polyarteritis nodosa (PAN) is a systemic necrotizing vasculitis that typically affects medium-sized muscular arteries. The clinical subsets of PAN are idiopathic, generalized, secondary hepatitis B virus (HBV) associated and cutaneous PAN. These clinical subsets are important because of their therapeutic implications. Virtually any organ system can be affected in generalized PAN, but this vasculitis tends…

    What Pharmacists Want Rheumatologists to Know

    May 18, 2019

    Involving pharmacists in the management of chronic diseases benefits patients, says Wendy Ramey, BSPharm, RPh, CSP, a clinical pharmacy specialist in rheumatology at the University of Kentucky, Lexington. She knows this personally. As someone with rheumatoid arthritis (RA), Ms. Ramey knows pharmacists can play an important role in patient education and encouraging adherence to medications….

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences